Early Development
Accelerating molecules through to proof-of-concept
Simplify early development and accelerate to proof-of-concept with the help of Quotient Sciences
Proof-of-concept
Proof-of-concept (POC) is a key milestone in the development of a new drug candidate. We understand the transition to POC needs to be fast and cost-effective.
With fully integrated capabilities from first-in-human testing to seamless drug product supply for patient trials, we simplify early development and accelerate molecules through to POC.
Rapid drug product optimization support
It's common for most new drugs to require some sort of reformulation or optimization during their development, whether to respond to suboptimal exposure profiles, to transition from an early development formulation to one suitable for chronic administration in patients, or as part of a life-cycle management strategy.
At Quotient Sciences, our unique Translational Pharmaceutics platform streamlines the drug product optimization process, enabling us to design, manufacture and obtain clinical data on new formulations in an accelerated timeframe all under a single organization and single clinical protocol. This approach improves formulation decision making, halves development timelines, and conserves API.
Resources
Read our related case studies
-
Info SheetIntegrated Programs: Early DevelopmentSimplify early development and accelerate to Proof-of Concept Proof-of-Concept (POC) is a key milestone in the development of a new drug candidate. At Quotient Sciences, we understand the increasing pressures on R&D budgets, therefore the need to transition molecules through early development to POC needs to be fast and cost-effective.
-
Case StudiesBioCryst Pharmaceuticals Case StudyBioCryst Pharmaceuticals is taking advantage of Quotient Sciences’ Translational Pharmaceutics® platform and First-In-Human program for the development of BCX4161, a promising candidate for the treatment of hereditary angioedema.
-
Case StudiesStealth BioTherapeutics Case StudyStealth BioTherapeutics is using real-time sterile manufacturing to enable a new route of administration.
-
Case StudiesMEI Pharma Case StudyMEI Pharma has leveraged Quotient's Translational Pharmaceutics® platform to expedite development of its next-generation cancer therapy ME-401.